CompletedPhase 4NCT01297777
Imatinib in KIT-negative Systemic Mastocytosis
Studying Mastocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospital Virgen de la Salud
- Principal Investigator
- Luis Escribano, MD, PhDInstituto de Estudios de Mastocitosis de Castilla La Mancha
- Intervention
- Imatinib Mesylate(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2015
Study locations (1)
- Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle, Toledo, Toledo, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01297777 on ClinicalTrials.govOther trials for Mastocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07328178Analysis of the Role of IgE Proteoforms in Health and DiseaseKU Leuven
- RECRUITINGPHASE4NCT06748001Avapritinib Rollover StudyBlueprint Medicines Corporation
- RECRUITINGNCT06466889Mastocytosis Registry (of Zurich)University of Zurich
- ACTIVE NOT RECRUITINGNCT06065007Quality of Life and Disease-related Symptoms in Individuals With Systemic MastocytosisUppsala University
- RECRUITINGPHASE1NCT06327685Avapritinib With Decitabine in Patients With SM-AHNH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06440148Relationship Between Circulating Sclerostin and Bone Lesions in Patients With MastocytosisMedical University of Lublin
- RECRUITINGNCT00044122Study of Factors Regulating Mast Cell ProliferationNational Institute of Allergy and Infectious Diseases (NIAID)